# Expanded Access of Pimavanserin for Patients With PD Psychosis

> **NCT02762591** · — · APPROVED_FOR_MARKETING · sponsor: **ACADIA Pharmaceuticals Inc.**

## Conditions studied

- Parkinson's Disease Psychosis

## Interventions

- **DRUG:** Pimavanserin tartrate

## Key facts

- **NCT ID:** NCT02762591
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762591, "Expanded Access of Pimavanserin for Patients With PD Psychosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02762591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*